ALHA
Ag85A-LpqH (AL) is a recombinant subunit vaccine that combines the T cell-stimulating antigen Ag85A with the humoral immunity-targeting antigen LpqH. It is constructed using the pET-21a(+) vector, expressed in E. coli BL21(DE3), and formulated with aluminum for subcutaneous administration.
Read MoreREA
A multifusion protein-based vaccine formulated with MPL/DDA.
Read MoreTBvac-1, TBvac-2, TBvac-10
TBvac-1, TBvac-2, and TBvac-10 use a recombinant tri-segmented Pichinde virus (PICV) vector (rP18tri) to express M. tuberculosis antigens. TBvac-1 and TBvac-2 encode Ag85B, EsxA/ESAT-6, and EsxH/TB10.4, with antigen locations swapped between S1 and S2 segments. TBvac-10 encodes Ag85B, EsxH/TB10.4, RpfA, and Rv1733c. Vaccine stocks are produced in BHK-21 cells from plaque purified virus.
Read MoreBCG-EVs
This vaccine comprises EVs derived from Mycobacterium bovis and Escherichia coli Nissle 1917. BCG-EVs carry multiple molecules, including known protective TB antigens. The EVs will be lyophilized to ensure physicochemical stability and eliminate the need for a cold chain. Owing to their acellular nature, the vaccine is suitable for infants and children, including those living…
Read MorePNx6
PNx6 is a modular, self-assembling and self-adjuvanting peptide-based vaccine candidate that is cold-chain independent. Each peptide building blocks consist of a linear arrangement comprising a 15-leucine (15L) self-assembly inducer moiety, a 15 amino acid Mtb epitope and a 9 amino acids HLA-E binding moiety, with each moiety separated by a triple lysine spacer.
Read More